ARS Pharmaceuticals (SPRY) News Today $3.58 -0.16 (-4.16%) As of 11:44 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest ARS Pharmaceuticals Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Has Average Price Target of $25.00October 26 at 6:13 AM | marketbeat.comHead-To-Head Analysis: Bausch Health Cos (NYSE:BHC) versus ARS Pharmaceuticals (NASDAQ:SPRY)October 19, 2026 | americanbankingnews.comSPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026October 5, 2026 | tmcnet.comARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRYOctober 5, 2026 | prnewswire.comSPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawOctober 5, 2026 | prnewswire.comARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud LawsuitOctober 2, 2026 | prnewswire.comARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRYOctober 2, 2026 | globenewswire.comARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff RoleOctober 2, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor HarmOctober 1, 2026 | globenewswire.comSPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawOctober 1, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRYOctober 1, 2026 | prnewswire.comSPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026October 1, 2026 | prnewswire.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Has Consensus Price Target of $25.00October 1, 2026 | marketbeat.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRYSeptember 30, 2026 | prnewswire.comARS Pharmaceuticals, Inc. (SPRY)September 30, 2026 | finance.yahoo.comBank of America Corp DE Makes New Investment in ARS Pharmaceuticals, Inc. $SPRYSeptember 30, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRYSeptember 29, 2026 | globenewswire.comSueWallSt Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - SPRYSeptember 29, 2026 | globenewswire.comSPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud LawsuitSeptember 28, 2026 | prnewswire.comARS PHARMACEUTICALS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRYSeptember 28, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor HarmSeptember 28, 2026 | globenewswire.comSPRY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ARS Pharmaceuticals Securities Lawsuit - Contact Levi & KorsinskySeptember 28, 2026 | globenewswire.comARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRYSeptember 28, 2026 | prnewswire.comSPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawSeptember 28, 2026 | prnewswire.comSPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026September 26, 2026 | globenewswire.comSPRY DEADLINE: ROSEN, TRUSTED INVESTOR RIGHTS COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRYSeptember 25, 2026 | globenewswire.comRobbins LLP Reminds SPRY Stockholders of the Pending October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action Against ARS Pharmaceuticals Inc.September 25, 2026 | globenewswire.comKaplan Fox Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors Who Suffered Losses to a Securities Class Action – Deadline is October 5, 2026September 25, 2026 | globenewswire.comKaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm Before Lead Plaintiff Deadline on October 5, 2026September 24, 2026 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRYSeptember 24, 2026 | prnewswire.comBragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff RoleSeptember 24, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor HarmSeptember 24, 2026 | globenewswire.comSPRY Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in ARS Pharmaceuticals Inc. Securities Class Action - Contact SueWallStSeptember 24, 2026 | prnewswire.comSPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawSeptember 24, 2026 | globenewswire.comSPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026September 24, 2026 | prnewswire.comKaplan Fox Alerts Investors to an Upcoming Deadline of October 5, 2026 in the ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Securities Class ActionSeptember 23, 2026 | theglobeandmail.comSPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action Notice - Contact Levi & KorsinskySeptember 23, 2026 | prnewswire.comKaplan Fox Reminds ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors with Significant Losses to Seek a Leadership Role Before Deadline on October 5, 2026September 23, 2026 | globenewswire.comKaplan Fox Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Seek Leadership in a Securities Fraud Lawsuit by October 5, 2026September 22, 2026 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRYSeptember 22, 2026 | globenewswire.comARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRYSeptember 22, 2026 | globenewswire.comKaplan Fox & Kilsheimer LLP Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026September 22, 2026 | theglobeandmail.comSPRY Deadline Alert: SueWallSt Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026September 22, 2026 | globenewswire.comARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRYSeptember 22, 2026 | prnewswire.comKaplan Fox & Kilsheimer LLP Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before October 5, 2026September 21, 2026 | theglobeandmail.comARS PHARMACEUTICALS DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities...September 21, 2026 | markets.businessinsider.comSPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud LawsuitSeptember 21, 2026 | prnewswire.comSPRY Stockholders with Large Losses Should Contact Robbins LLP About Leading the ARS Pharmaceuticals Inc. Class Action Before the October 5, 2026 DeadlineSeptember 21, 2026 | prnewswire.comSPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawSeptember 21, 2026 | globenewswire.comKaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors with Significant Losses to Contact the Firm Before October 5, 2026September 21, 2026 | globenewswire.com ARS Pharmaceuticals Media Mentions By Week ARS Pharmaceuticals Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRY News Sentiment▼1.580.69▲Average Healthcare News Sentiment ARS Pharmaceuticals News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRY Articles This Week▼27▲SPRY Articles Average Week ARS Pharmaceuticals Trends on MarketBeatThis week vs. last weekNew Followers1Searches1Page Views2,254-8% Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies PAHC News Today OCUL News Today INVA News Today CMPS News Today GPCR News Today PCRX News Today ETON News Today RAPP News Today GHRS News Today LBRX News Today News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for ARS Pharmaceuticals dated 10/26/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredThe chip inside every TeslaEvery Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
